Reporting from the ESMO Virtual Congress 2020, Sandro Pignata features results from the ovarian cancer studies performed in the advanced setting, IMagyn050/GOG 3015/ENGOT-OV39 which explored a combination of bevacizumab with immune checkpoint inhibitor atezolizumab, and PAOLA-1 about maintenance treatment with a combination of olaparib and bevacizumab that confirmed the important role of PARP inhibitors in the management of ovarian cancer. He also discusses the results from the INOVATYON trial looking at t
Hide player controls
Hide resume playing